Neural progenitors derived from human embryonic stem cells are targeted by allogeneic T and natural killer cells

Neural progenitor cells (NPC) of foetal origin or derived from human embryonic stem cells (HESC) have the potential to differentiate into mature neurons after transplantation into the central nervous system, opening the possibility of cell therapy for neurodegenerative disorders. In most cases, the transplanted NPC are genetically unrelated to the recipient, leading to potential rejection of the transplanted cells. Very few data provide reliable information as to the potential immune response of allogeneic neural progenitors derived from HESC. In this study, we analyzed in vitro the allogeneic immune response of T lymphocytes and natural killer (NK) cells to NPC derived from HESC or of foetal origin. We demonstrate that NPC induce T‐cell stimulation and a strong NK cytotoxic response. NK‐cell activity is unrelated to MHC‐I expression but driven by the activating NKG2D receptor. Cyclosporine and dexamethasone previously used in clinical studies with foetal NPC did not only fail to prevent NK alloreactivity but strongly inhibited the terminal maturation from NPC into mature neurons. We conclude that allogenic transplantation of NPC in the central nervous system will most likely require an immunosuppressive regimen targeting allogenic T and NK cells, whereas possible interference with the differentiation of NPC needs to be carefully evaluated.

[1]  Luc Stoppini,et al.  Development of Human Nervous Tissue upon Differentiation of Embryonic Stem Cells in Three‐Dimensional Culture , 2009, Stem cells.

[2]  K. Krause,et al.  Neural commitment of embryonic stem cells: molecules, pathways and potential for cell therapy , 2008, The Journal of pathology.

[3]  W. Paulus,et al.  The Tumorigenicity of Mouse Embryonic Stem Cells and In Vitro Differentiated Neuronal Cells Is Controlled by the Recipients' Immune Response , 2008, PloS one.

[4]  R. Bakay,et al.  Therapeutic potentials of human embryonic stem cells in Parkinson’s disease , 2008, Neurotherapeutics.

[5]  R. Young,et al.  Stem Cells, the Molecular Circuitry of Pluripotency and Nuclear Reprogramming , 2008, Cell.

[6]  M. Fujiki,et al.  Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. , 2008, Transplantation.

[7]  B. Segal The role of natural killer cells in curbing neuroinflammation , 2007, Journal of Neuroimmunology.

[8]  J. Moynihan,et al.  Brain behavior and immunity: Twenty years of T cells , 2007, Brain, Behavior, and Immunity.

[9]  D. Cornfield,et al.  The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. , 2007, Blood.

[10]  F. Edwards,et al.  Differential development of neuronal physiological responsiveness in two human neural stem cell lines , 2007, BMC Neuroscience.

[11]  L. Moretta,et al.  Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2- versus IL-15-activated NK cells. , 2007, Blood.

[12]  P. Parham,et al.  Do NK-cell receptors and alloreactivity affect solid organ transplantation? , 2006, Transplant immunology.

[13]  M. Martelli,et al.  Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. , 2006, Blood.

[14]  E. Simpson A historical perspective on immunological privilege , 2006, Immunological reviews.

[15]  M. Carrington,et al.  The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. , 2006, Annual review of genomics and human genetics.

[16]  Uwe Völker,et al.  2‐DE proteome analysis of a proliferating and differentiating human neuronal stem cell line (ReNcell VM) , 2006, Proteomics.

[17]  J. Villard Immunity after organ transplantation. , 2006, Swiss medical weekly.

[18]  J. Cidlowski,et al.  Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. , 2005, The New England journal of medicine.

[19]  L. Moretta,et al.  Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. , 2005, Immunology letters.

[20]  A. Barbari,et al.  Cyclosporine lymphocyte maximum level: a new alternative for cyclosporine monitoring in kidney transplantation. , 2005, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[21]  S. Falci,et al.  Low immunogenicity of in vitro-expanded human neural cells despite high MHC expression , 2005, Journal of Neuroimmunology.

[22]  M. Uhrberg The CD107 mobilization assay: viable isolation and immunotherapeutic potential of tumor-cytolytic NK cells , 2005, Leukemia.

[23]  P. Parham MHC class I molecules and kirs in human history, health and survival , 2005, Nature Reviews Immunology.

[24]  Anders Björklund,et al.  Cell transplantation in Parkinson's disease: how can we make it work? , 2005, Trends in Neurosciences.

[25]  Li Li,et al.  Human Embryonic Stem Cells Possess Immune‐Privileged Properties , 2004, Stem cells.

[26]  D. Hess,et al.  Intracerebral Xenotransplantation of GFP Mouse Bone Marrow Stromal Cells in Intact and Stroke Rat Brain: Graft Survival and Immunologic Response , 2004, Cell transplantation.

[27]  J. Twiss,et al.  Effects of Altered Expression and Localization of Cyclophilin A on Differentiation of p19 Embryonic Carcinoma Cells , 2003, Cellular and Molecular Neurobiology.

[28]  Vesna Sossi,et al.  A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.

[29]  S. Saidman,et al.  Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation. , 2003, Experimental hematology.

[30]  D. Kaufman,et al.  Immunosuppression: practice and trends , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  Maya Schuldiner,et al.  Characterization of the expression of MHC proteins in human embryonic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[33]  C. Olanow,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[34]  R. Lechler,et al.  Allorecognition , 2001, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[35]  K. Prasad,et al.  Effects of Altered Cyclophilin A Expression on Growth and Differentiation of Human and Mouse Neuronal Cells , 2001, Cellular and Molecular Neurobiology.

[36]  D. Spencer,et al.  Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. , 1992, The New England journal of medicine.

[37]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[38]  Patrik Brundin,et al.  Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis , 1988, Brain Research Reviews.

[39]  D. Mason,et al.  The fate of allogeneic and xenogeneic neuronal tissue transplanted into the third ventricle of rodents , 1986, Neuroscience.

[40]  Mary Anne Wheeler,et al.  Stem , 1985 .

[41]  P. Brundin,et al.  From bench to bed: the potential of stem cells for the treatment of Parkinson’s disease , 2007, Cell and Tissue Research.

[42]  G. Dellgren,et al.  Human embryonic stem cells are immunogenic in allogeneic and xenogeneic settings. , 2006, Reproductive biomedicine online.

[43]  Micha Drukker Immunogenicity of embryonic stem cells and their progeny. , 2006, Methods in enzymology.

[44]  Lewis L Lanier,et al.  NK cell recognition. , 2005, Annual review of immunology.

[45]  R. Biassoni,et al.  Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. , 2001, Annual review of immunology.

[46]  R. Lechler,et al.  Allorecognition. [Review] [29 refs] , 2001 .